INTRODUCTION
Sera from vaccinees are being evaluated for a wide range of antibody activities, including the presence of neutralizing and for future in vitro and animal model studies were drafted that It was withdrawn when it became evident that it predisposed would address the gaps in our knowledge about the risks posed some recipients to an exaggerated illness referred to as atypical by ADE in HIV vaccine trials and provide a basis for decision measles syndrome. ' 3 The pathogenesis of this syndrome is not making in HIV vaccine development, known and in vitro ADE was not evaluated. Therefore, in RSV
Immune-mediated enhancement of viral diseases other
and measles, although immune-mediated enhancement of disthan HIV ease clearly occurs, the mechanism of enhanced disease and the possible role of ADE of infection are not understood. Immune-mediated disease enhancement in several viral disAnimal viral diseases. Feline infectious peritonitis virus eases, including lentiviral diseases other than HIV, was re-disease (FIPV) is a coronavirus that causes a fatal multisystem viewed in a session chaired by S. Haistead (Rockefeller Foun-pyogranulomatous disease in kittens and cats. F. Scott (Cornell dation). There are examples of enhanced clinical disease in both University. Ithaca, NY), reviewed the evidence for immunevaccinated and previously exposed animals and humans. These mediated disease and the mechanism of enhancement of FIPV. are briefly reviewed below. A more comprehensive discussion The primary target for viral replication in vivo is believed to be of this subject occurs elsewhere. "-3 the macrophage. '4 Cats with active or passive immunity to FIPV Human viral diseases. The human disease for which im-often develop an accelerated and more fulminant disease course mune-mediated enhancement is best understood is dengue. on FIPV challenge than seronegative cats, and kittens immuDengue viruses, members of the Flaviviridae family, occur as nized with a recombinant vaccinia virus expressing the spike four antigenically distinct serotypes. After a short period of protein of FIPV succumbed earlier than did control animals. '5 cross-protection, individuals infected with one serotype are fully The role of Abs in promoting more severe disease has been susceptible to infection with other serotypes. Dengue fever, documented by passive transfer of FIPV-reactive immune sera usually a benign self-limited febrile illness, can occasionally or purified immunoglobulin (Ig) to seronegative cats. 16 Furtheroccur as a severe syndrome called dengue hemorrhagic fever/ more, in vitro FIPV infection of primary feline peritoneal dengue shock syndrome (DHF/DSS). Such severe manifestamacrophages is enhanced in the presence of FIPV Abs. 14 tions almost always occur in individuals with preexisting Abs to Although definitive experiments demonstrating that in vitro one dengue serotype (either from prior infection or of maternal ADE is predictive of exaggerated clinical disease have not yet origin), and subsequent exposure to a different serotype. 4 been performed, FIPV vaccine development has been hindered In vitro, heterotypic dengue Abs can enhance dengue virus by the in vitro and in vivo observations of immune enhancement infection of human M/M cells.- 5 In a prospective study of school of FIPV infection. children in Thailand, in vitro enhancing activity of serum was a There have also been reports of disease enhancement after powerful predictor of DHF/DSS among dengue-immune chilvaccination of animals with killed whole-virus vaccines for dren. 6 This was the first human study to establish a clear link bluetongue disease of cattle and Aleutian disease of mink. 3 Of between serum ADE and enhanced clinical disease. It is now particular interest is a study of Aleutian disease virus in which 8 widely accepted that ADE plays an important role in dengue of 10 vaccinated mink, but none of 4 control animals, developed infection, and the theoretical risk that dengue vaccination might Aleutian disease after oral challenge with a standardized infecpotentiate more severe disease has delayed the development and tious dose of virus. 7 This is one of the few studies clearly testing of dengue vaccines. 7 Of note, there are several examples demonstrating that immune-mediated enhancement can lead to among the flaviviruses in which serum ADE activity has been an increased susceptibility to infection as well as a more severe demonstrated in vitro (against both homologous and heterolo-disease course. gous flavivirus species) despite the fact that in vivo disease Lentiviraldiseases. Equine infectious anemia virus (EIAV) enhancement does not occur.-" 8 in fact, successful vaccines for is a lentiviral infection of horses that generally causes a synyellow fever and Japanese encephalitis have been used in drome of fever, anorexia, and anemia with cyclical recurrences millions of persons and do not appear to enhance infection of during the first year of disease. Subsequently, horses may either homologous or heterologous flaviviruses. 3 become asymptomatic or develop a chronic wasting syndrome. Immune-mediated disease enhancement has also been de-Data were presented that demonstrated in vivo immune-mediscribed in individuals vaccinated against respiratory syncytial ated disease enhancement of vaccinated ponies challenged with virus (RSV). Following immunization with a formalin-inacti-EIAV (R. Montelaro, University of Pittsburgh, PA). In experivated whole-virion RSV vaccine, children were at increased risk ments with an inactivated whole-virus vaccine, horses chalof severe RSV disease compared with control groups. This lenged with homologous virus were protected from infection effect was dramatically illustrated in four parallel studies con-whereas animals challenged with a heterologous viral strain ducted between 1966 and 1967.9 Subsequent evaluation of became infected but were protected from disease. "' In contrast. vaccinee serum from one of the studies revealed high titers of immunization with a baculovirus-expressed EIAV envelope "non-nonfunctional" (i.e., nonneutralizing) Abs compared to glycoprotein vaccine generated no protection against homolonaturally infected children. ") Although there are no reports of gous viral challenge and significant enhancement of disease enhancement studies on sera from the vaccinated children, severity was observed when the immunized ponies were chalparticularly those with enhanced clinical disease, human sera lenged with a heterologous EIAV strain. No in vitro data on containing RSV-specific Abs can enhance RSV infection of the ADE in sera from vaccinated ponies are yet available. macrophage cell line U937. " Furthermore, RSV can replicate Caprine arthritis-encephalitis virus (CAEV) and visna virus in vitro in human peripheral blood M/M cells. 2 are ungulate lentiviruses. CAEV causes a gradually progressive Another example is the killed measles vaccine, which was debilitating arthritis in goats, whereas visna virus causes a administered to over 500,000 children between 1963 and 1967. chronic progressive paralyzing disease of the central nervous
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•, J O E e t w Presbyterian Medical Center) and is summarized in Table I JuslificatiL;, Fc,,R Fc.RII served, whereas enhancement is seen at higher dilutions. En-were necessary to mediate the enhancing effect of serum and that hancement has also been reported as an "enhancement ratio" the increased viral expression seen in this assay was a result of (ratio of viral yield in the presence of Ab to that in the absence of increased viral binding to MT-2 cells. 32 33 This complementAb) for each serum dilution. In different assay systems, the mediated ADE (C'-ADE) requires cell receptors for both C14 magnitude of enhancement of HIV infection (measured by level and CR type 2 (CR2) 34 and was seen with the IIIB and RF strains of viral expression) has ranged from barely 2-fold to greater than of HIV-1. Sera from 95% of HIV-infected individuals (all stages 100-fold. 3 o Likewise, the highest serum dilution showing ADE of disease) show ADE when assayed in this manner. -('Most sera ranges from 101 to 105. The method of measuring and express-demonstrate neutralizing activity at high concentrations and ing ADE activity can be of critical importance in attempting to C'-ADE at subneutralizing concentrations. Interestingly, comcorrelate in vitro ADE with an in vivo effect. For example, in plement depletion of sera eliminated ADE activity and usually secondary dengue infections, serum-enhancing activity of undi-revealed significant serum neutralization activity measured in luted sera was a significant risk factor for severe dengue illness the same assay. M. Wainberg (McGill University, Montreal, when human peripheral blood mononuclear cells (PBMCs) were Quebec, Canada) reviewed data that C'-ADE also occurs when used as indicator cells. In contrast, end-point ADE titer (highest Epstein-Barr virus (EBV)-transformed human B cells are used titer showing enhancing activity) was not predictive, and para-at target cells.
3 '" 36 doxically was higher in children without severe illness. 6 A second type of ADE requiring the FcR rather than the CR The relationship between neutralizing and enhancing Abs is has also been described in which HIV-specific Ab, but not of particular interest. At any given serum dilution, the overall complement, is required for enhancement to occur. FcR-medieffect on viral growth in vitro is likely to be the net sum effect of ated ADE (FcR-ADE) of infection of the human monocytic cell neutralizing and enhancing Abs. In complex mixtures of cells, line U937 has been demonstrated using the IIIB strain of such as exist in vivo in humans, or even in vitro in PBMCs, Abs HIV-1.37-41 Others have reported FcR-ADE of infection of in a given serum may protect some cells from infection while primary human lymphocytes and macrophages, using several simultaneously increasing the rate of infection of others. Even HIV-I isolates grown in PBMCs.
42
. 43 In these assays, low without a net increase in the number of cells infected, enhancing levels of FcR-ADE have been found in most HIV immune Abs may alter pathogenesis by retargeting virus to different sera, 3 7 and like C'-ADE, serum-enhancing activity usually populations of cells. These issues can be partly addressed by occurs at subneutralizing concentrations. In contrast, Shadduck using selected cells as targets for assays or by selecting a virus et al. found that HIV-I infection of human monocytes and with specific cell tropism (e.g., M/M cells) features. Attention peritoneal macrophages was not facilitated by any of 14 human to the nuances of such in vitro measurements will ultimately HIV-I-seropositive sera.44 This result was consistent for four facilitate our ability to correlate in vitro measurements with viral isolates and in the presence or absence of complement. clinical outcomes of trials. Most reports of FcR-ADE have described a requirement for the CD4 receptor; however, in one report, using primary human nvitro data for antibody-dependent enhancement by macrophages, CD4 was not found to be necessary for FcRsera from HIV-infected individuals ADE. 42 Some of the major parameters that vary among in vitro enhancement assays are listed in Table 2 .
Several groups of investigators have independently demon-
Efforts have attempted to define whether there are specific strated ADE activity in sera from HIV-infected individuals. In epitopes responsible for ADE. Robinson et al. have demon-1987, Robinson et al. noted that a factor intrinsic to HIV-strated that human monoclonal antibodies (MAbs) to the immuseropositive sera caused an increase in cytopathic effect and nodominant region of gp4l can mediate C'-ADE. 45 ' Evaluasyncytium formation in human transformed cells (MT-2). 3 ' tion of gp120 MAbs for similar C'-ADE activity is in progress. Subsequent evaluation (reviewed by E. Robinson, University of A human monoclonal antibody that binds to a conformational California, Irvine, CA) demonstrated that Ab and complement epitope in the carboxyl half of gpl20 has been reported to 'Serum dilutions for which ADE is described.
mediate FcR-ADE. 47 Further evaluations of in vitro correlates boosted with autologous cells infected in vitro. Heat-inactivated of immune protection and enhancement for HIV are needed to sera at a dilution of 1:100 from all three demonstrated neutralizassess the biological significance of specific epitopes in a ing and not enhancing activity of HIV-IIIB infection of primary vaccine candidate. human macrophages." 2 F. Ennis (University of Massachusetts, Because our central concern is whether ADE plays a role in Amherst) and D. Montefiori (Vanderbilt University, Nashville, vaccinated individuals exposed to primary "field" isolates of TN) reviewed results from two NIAID-sponsored phase I vac-HIV, the analysis of such isolates is of primary importance. C. cine trials. Of 24 seronegative volunteers vaccinated with a Hanson (California Department of Health, Berkeley, CA) pre-baculovirus-expressed recombinant gpl60 product, after the sented data that HIV grown in human PBMCs is more susceptithird boost 6 had low-titer C'-ADE activity measured in MT-2 ble to C'-ADE and less susceptible to neutralization than is HIV cells, 3 none of 13 sera obtained after the second boost demongrown in a transformed cell line (H9). Furthermore, antiserumstrated FcR-ADE measured in U937 cells. 54 In another trial virus pairs showing strong C'-ADE when assayed on MT-2 cells evaluating primary vaccination with a recombinant vaccinia do not show C'-ADE in a PBMC indicator system. S. Kliks virus expressing gpi60 followed by booster immunization with (University of California, San Francisco, CA) reported experi-gpl6O, C'-ADE activity was detected in 7 of 10 vaccinees. ments using primary PBMCs for both viral growth and indicator Several other candidate HIV-I vaccines are currently undergocells; replication of a M/M-tropic HIV isolate could be enhanced ing phase I and/or phase II testing through the AIDS Vaccine by HIV immune sera whereas growth of the T cell-tropic isolate Evaluation Group (AVEG) of DAIDS, NIAID. Studies are (HIV-SF2) could not. Clearly, the type of cells used as indica-ongoing or planned to evaluate the sera from vaccinees for the tors for viral replication, as well as the type of cells used to grow presence of neutralizing and enhancing Abs. HIV-I in culture, can affect in vitro neutralization and enhanceOf note, C'-ADE has been demonstrated in rhesus macaques ment results. The explanations for these observations will vaccinated with whole inactivated SIV vaccines, or with glycorequire further study.
protein or core protein-enriched subunit vaccines. 5 In these SIV Several limited studies evaluating the relationship between challenge studies, as in dengue in children, 6 high serum titers of serum ADE activity and stage of disease have found no consis-enhancing Abs correlated better with protection than with tent link for in vitro-detected ADE with HIV disease progresinfection." 48 In contrast. Toth and colleagues found some in vitro assays will detect ADE in some sera from vaccinees. serum C'-ADE activity in 12 of 19 symptomatic vs. 4 of 20 Because ongoing analysis of sera will be from phase 1/1I immunoasymptomatic HIV-infected patients. 4 ' Both of these studies genicity trials of HIV vaccinees, we do not expect to determine were done using the IIIB strain of HIV-I and transformed cells in vivo correlates for these in vitro data. Therefore, interpretation of as targets. Homsy et al., using PBMCs as target cells, reported the significance of these results will be limited until further in vivo that serum.-enhancing activity (FcR-ADE) against homotypic studies are performed. This issue is discussed further in Evaluation virus was present in I of 5 asymptomatic vs. 6 of I I symptom-of the Antibody-Dependent Enhancement Risk Associated with atic HIV-infected patients. Furthermore the serum-enhancing Particular HIV Vaccine Candidates. activity of three of five individuals followed for 1-3 years appeared to increase over time. 43 As noted, the assay method-HIV genetic variation: potential impact of genetic ology differed significantly among these studies; in the C'-ADE subtypes or serotypes of HIV-! on the risk of studies, the IIIB strain of HIV was used to infect transformed cell lines, whereas in the FcR-ADE study homotypic virus was antibody-dependent enhancement ) presented data that viruses Although it is clear that naturally infected humans have representing two distinct genetic subtypes can be distinguished enhancing antibodies to HIV, the type of immune response using a neutralizing antibody assay. 58 Thus, it is possible that generated after vaccination is more pertinent to the question of antigenically distinct serotypes of HIV-I exist. Current vaccine ADE risk in vaccinees. In 1989, Homsy et al. reported that candidates are based on prototype viral strains (HIV-MN, serum from a guinea pig hyperimmunized with HIV-SF128A HIV-IIIB/LAI, HIV-SF2), which are all representatives from a could enhance HIV infection of PBMCs. 42 In addition, data single genetic subtype. Therefore, international vaccine trials showing that sera from rabbits immunized with several types of planned with current vaccine candidates could result in immu-HIV gpl120 or V3 loop peptides enhanced HIV-IIIB infection of nization with a serotype of HIV that is different from that U937 cells 50 ' 5 ' were reviewed by S. Jiang and R. Neurath (New prevalent in the population of vaccinees. The dengue and EIAV York Blood Center, New York, NY).
experience of enhanced disease after infection with a heteroloIn human vaccinees, Bernard et al. evaluated three individu-gous serotype heightens the concern that an analogous scenario als immunized with vaccinia virus expressing gpl60 and could occur in HIV vaccine trials.
Summarizing the risk of antibody-dependent Epidemiological surveys in HIV-infected individuals enhancement in HIV vaccine trials
S. Halstead discussed the possibility that if ADE of HIV In summary, there are several factors which, when viewed infection occurs, it might be found in instances in which an together, raise concern that ADE of HIV infection is a potential individual is exposed to HIV in the presence of anti-HIV risk in human HIV vaccine trials. We know that immune-antibodies. HIV infection acquired by blood (plasma) transfumediated disease enhancement occurs in several viral diseases, sion and HIV acquired neonatally by infants who circulate including lentiviral diseases (e.g., EIAV). Manifestations of maternal HIV antibodies are examples that comply with the enhancement include increased viremia, shortened incubation conditions under which anti-HIV antibody should be present and period, altered pathogenesis, more severe disease outcome, and ADE might occur. Careful epidemiological studies of individuan increased susceptibility to infection. In dengue and FIPV, als exposed to HIV in this manner, with matched controls, might evidence indicates that ADE of M/M cells in vivo is the probable answer the question of whether ADE occurs in HIV disease and mechanism of enhanced disease. Viral replication in host M/M what its manifestations are. Negative studies would be reassurcells is characteristic of most of the diseases for which immune ing with respect to the putative risk of ADE after HIV vaccinaenhancement has been described, and is well described in tion. lentiviral diseases, including HIV. Sera from HIV-t-infected Example¢ of such epidemiological studies were discussed, persons contain antibodies that enhance the growth of HIV including (I) retrospective evaluations of transfusion-infected in vitro and it is reasonable to expect that some sera from HIV-I individuals comparing plasma-containing vs. plasma-free prodvaccinees will also contain enhancing antibodies. Finally, the ucts, and (2) mother/infant studies attempting to correlate the known genetic diversity of HIV-I worldwide, the possibility of risk of HIV transmission with in vitro measurement of neutralantigenically distinct serotypes, and the fact that current vaccine izing and enhancing antibodies. candidates represent a single genetic subtype, heighten concern that immunization could enhance heterologous subtypes of HIV/SIV animal model experiments HIV-I (similar to what occurs in dengue and EIAV).
These concerns regarding ADE in vaccine trials are partially IfnADE of Hm V infection occurs i m
vivo. vaccinees with partial
balanced by the observation that enhanced disease has not yet or incomplete immunity might be more susceptible to HIV been observed in challenge experiments of SIV-vaccinated infection, or manifest a more severe disease course. In the monkeys, despite the fact that in some cases complement-setting of a large HIV vaccine efficacy trial, probably the most dependent enhancing Abs were present in high titer at the time of serious adverse outcome is an increased incidence of HIV challenge." Also of note, ADE of virus growth in vitro has been infection in vaccinees. Therefore, animal experiments that described in numerous viral diseases and often has no in vivo would address this risk are of primary importance. With regard correlate. -' Because we currently lack clinical evidence for ADE to assessment of the risk of ADE in HIV vaccine trials, HIV/SIV in HIV disease, there are no in vivo correlates for the in vitro animal models have two primary objectives: (I) to determine if observations of ADE. Therefore, it is not possible to accurately susceptibility to infection is enhanced by active or passive assess the significance of in vitro measurements in naturally immunization prior to viral challenge, and (2) to determine if the infected or immunized individuals. An HIV animal model is progression of disease is augmented by active or passive immurequired to advance our understanding of the potential risk of nization prior to viral challenge. ADE in HIV vaccine trials. Such HIV/SIV animal model Experiments addressing the first issue would determine if the experiments are discussed in the next section. Our knowledge of animal ID 50 (50% infectious dose) of the challenge virus is immune-mediated enhancement in other viral diseases, espe-lowered after active or passive immunization. Susceptibility to cially lentiviral diseases, and data for in vitro ADE in HIV heterologous as well as homologous strains of challenge virus disease, do indicate that well-directed studies are needed to should be considered and close measurements made of the level further address the risk of ADE in HIV vaccine trials. However, of circulating neutralizing and enhancing antibodies present at there is currently insufficient evidence to halt or delay the the time of challenge. Passive immunization studies should be development of specific HIV vaccine candidates or early clinical designed to establish circulating antibody levels in animals at trials with these candidates. The next two sections suggest, in concentrations shown to enhance viral growth in vitro. Studies general terms, key in vitro and animal experiments that could designed to eval'iate potential enhancement of disease progresbetter define the potential risk of ADE, including a discussion of sion should be able to make multiple measuremcnts of (he the evaluation of individual vaccine candidates prior to large-humoral immune response and assess several outcome meascale efficacy trials. The ideal animal model for evaluating the risk of ADE in HIV SIV primate model. SIV is the primate lentivirus most vaccine trials would have several characteristics: (1) ability to closely related to HIV-I, and is genetically closely related to support productive infection with HIV-I field isolates represent-HIV-2. It shares many biological properties with HIV-I, including divergent genetic subtypes, (2) development of an immuno-ing CD4 lymphocyte and M/M tropism, and cell entry via the deficiency syndrome similar to AIDS in humans, and (3) CD4 receptor. 6 1 2 Experimental inoculation of SIV into several availability of sufficient numbers of animals. Several animal macaque species induces an immunodeficiency syndrome strikmodels using HIV-I or SIV were discussed with respect to their ingly similar to AIDS in human beings. 63 There are several utility in evaluating the risk of ADE in HIV vaccine trials. These different well-characterized strains of SIV, including a variety are briefly summarized below, of pathogenic molecular clones, each of which produces a HIV-I animal models. Currently the only animals that are slightly different clinical syndrome. Many of these viral strains susceptible to infection with HIV-I and could be utilized to have been titrated in vivo in macaques and are readily available study HIV-I immune-mediated enhancement are the chimpanfor experimental utilization. In the SIV model, therefore, chalzee and the severe combined immunodeficiency (SCID) mouse.
lenge viruses may be chosen that vary with respect to pathogeAlthough there has been a report of HIV-I infection of pig-tailed nicity, viral burden, and mean time to death. Furthermore, by 'nacaques (Macaca nemestrina), this model will require further using molecular clones, specific epitopes responsible for endevelopment before it can be used in enhancement studies. 9 hancement can be mapped and the corresponding sequences in The chimpanzee is the only primate species available that may the clone modified as desired. be infected with HIV-I and therefore employed for studying
The major limitations of the SIV model are the inability to protective vaccine efficacy. Unfortunately, there are several evaluate specific HIV-I vaccine candidates (comparable SIV major limitations to this model even though infected chimpananalog vaccines must be constructed) and its inability to provide zees seroconvert with antibodies to all major HIV-I-encoded specific information concerning immunological determinants of structural proteins and HIV-I can be isolated from their PBMCs.
immune-mediated enhancement of HIV-I infection. As previChimpanzees are not susceptible to productive infection with all ously discussed, disease enhancement has not been observed in HIV-I isolates in vivo. The only two strains of HIV-l success-numerous experiments designed to evaluate vaccine efficacy in fully titrated in chimpanzees in vivo are HIV-IIIB/LAI and more SlV. However, additional experiments designed specifically to recently HIV-SF2 (A. Schultz, Division of AIDS, NIAID, NIH, detect manifestations of in vivo enhancement such as increased Bethesda, MD), and long-term persistent viremia in chimpansusceptibility to a low-dose infection or advanced progression of zees has been documented only with variants of HIV-IIIB/LAI. disease would be informative. Certainly, the absence of in vivo In fact, virtually all other HIV-I isolates tested replicate poorly, enhancement in SIV studies would be reassuring with respect to if at all, in chimpanzee PBMCs (P. Zack, WRAIR). This the potential risk of ADE in HIV vaccine trials. restriction seriously limits the capability to perform immune Chimeric SIV/HIV (SHIV) primate model. Two groups enhancement challenge experiments using specific HIV-I field (Li et al., and Shibata et al.) have reported the productive isolates, and precludes experimental studies using heterolr:-ous infection of cynomolgus macaque monkeys with chimeric viviral challenge groups. Another disadvantage is that HIV-I ruses that express the Gag and Pol proteins from SIV, and the infection produces no clinical disease in chimpanzees. This Env proteins of HIV-I.64"65 These chimeras remain infectious limitation restricts utilization of the model to determine if there for nonhuman primates because the in vivo host range is is immunologically mediated enhanced disease progression.
predominantly determined by Gag and Pol, and because HIV Finally, chimpanzee experiments must be limited to small and SIV both use the same receptor to infect host cells. Because numbers of animals and are expensive to conduct. These envelope glycoproteins are believed to be the principal targets of drawbacks may limit the utility of the HIV chimpanzee model protective immunity in lentiviral diseases,"' 67 they are likely to for study of in vivo enhancement.
be equally important for immune-mediated enhancement. The-A second animal model for HIV-I infection has been de-oretically, therefore, the SHIV model could overcome the scribed using SCID mice reconstituted with human PBMCs limitations of the SIV model by allowing infection of macaques (hu-PBL-SCID) or human fetal thymus, lymph node, or liver with SHIV molecular constructs containing en' genes from tissue (SCID-hu). In both types of SCID mice models, trans-genetically divergent HIV-I viruses. This model, however, still planted human tissue and IgG have been detected for up to 6-12 remains under development. Although macaques were successmonths, and in both models SCID mice are susceptible to fully infected and antibodies detected to both HIV-I envelope infection with HIV-.611. 6 Potential advantages of this model and SIV Gag proteins, virus was difficult to recover beyond 4 include the ability to infect mice with most HIV-I isolates, to months postinoculation. Additionally the absence of clinical reconstitute mice with cells from human vaccinees, and to signs of immunodeficiency in any of the infected macaques perform passive antibody transfer experiments. Unfortunately demonstrated that the SHIV construct was less virulent than the there are several limitations to the HIV-SCID mouse model. The parent SlV clone. Construction of SHIV chimeric viruses is extent of reconstitution may vary with the human donor source, difficult because the SIV env gene normally overlaps the SIN implying that the number of human cells available for infection regulatory genes and introduction of HIV-I env must be accomwill also differ with the donor. Additionally, high concentrapanied by certain HIV-I regulatory genes. Furthermore it is not clear whether SHIVs constructed using env from other/all HIV-I display neutralizing activity against genetically similar viruses strains will retain the capability to infect macaques in vivo. and no neutralizing activity, but rather enhancing activity, Currently, therefore, no animal model is available that is against genetically divergent HIV-l isolates, we would be permissive for productive infection with multiple HIV-I isolates hesitant to test that product in a population likely to be exposed and that subsequently develops an immunodeficiency syn-to the divergent strain of HIV-l. In such a scenario, careful drome. Despite its limitations, the SIV model fulfills many of animal model experiments, as discussed above, would be the criteria required to study immune-mediated enhancement required to further evaluate the potential risks and benefits of the and is immediately available. The concern that immune-medivaccine product. ated enhancement is a risk factor for HIV vaccine trials would be significantly reduced if prospectively designed experiments using SIV fail to find evidence demonstrating this phenomenon. SUMMARY Theoretically, the chimpanzee model could be used to evaluate enhanced susceptibility to infection after vaccination, although
Concern that ADE of HIV infection could occur in vivo, as a available viral strains for challenge are limited. With further result of HIV immunization, has arisen for several reasons. development, other animal models using HIV-I or its genes may Immune-mediated disease enhancement occurs in several huprove to be useful. man and animal viral diseases, including lentiviral diseases. The authors thank Susan Muir (Rockefeller Foundation) for progress in development of HIV-I/SHIV animal models, we her outstanding assistance in planning the workshop. We thank should carefully obtain in vitro data on enhancing and neutraliz-Drs. G. Eddy, M. Lewis, Y. Rosenberg, and E. Hall for their ing antibody activity in sera from HIV-I vaccine volunteers, valuable discussions. 
